Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.75 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from NewLink Genetics.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®


February 10, 2018
InterContinental New York Times Square
300 W 44th St,
New York, NY 10036

Overview

PER’s 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a 1-day educational conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with melanoma and other cutaneous malignancies.

Led by world-renowned experts Omid Hamid, MD and Jeffrey Weber, MD, PhD, this international symposium, now in its 14th year, will provide physicians with the tools they need to personalize care for every patient they treat. Sessions will include presentations on advances in immunotherapy, the latest on targeted therapies, the benefits of regional therapy, how to use predictive and prognostic modeling, how to manage treatment-related adverse events associated with emerging strategies, and more! This year’s symposium will once again feature the dynamic and interactive Medical Crossfire® format, where experts will engage in a rigorous debate to answer your questions, and reach consensus on ongoing paradigm shifts. This fast-paced and interactive forum will once again prove highly practical to physicians who treat patients with skin cancer and provide them with unmatched access to the leading experts. Join us in New York, and together, we’ll meet the challenges currently facing the field!

What you will learn at the International Symposium on Melanoma!

  • The latest strategies on checkpoint inhibitor strategies, when to use single-agent or combination regiments
  • Insights into the role of other immunotherapy targets including OX40, GITR, IDO, and more
  • Current and emerging combinations to treat BRAF-mutant melanoma
  • Expert perspectives on the management of regional disease and how to prevent recurrence
  • Evolving strategies to mitigate treatment-related toxicities with targeted and immunotherapies

Acknowledgement of Commercial Support

This activity is supported by an educational grant from NewLink Genetics.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Choose treatment based on patient characteristics, such as age and performance status.
  • Assess the roles of regional therapies, targeted therapies, and immunotherapies in the treatment of patients.
  • Review strategies for mitigating and managing adverse events related to therapy.
  • Describe current and emerging strategies for individualizing therapy.
  • Evaluate emerging clinical data regarding new regional therapies, targeted therapies, and immunotherapies in treating melanoma and other cutaneous malignancies.


Program Co-Chairs

Jeffrey Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY


Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies – The Angeles Clinic and Research Institute
Director of Experimental Therapeutics, Cedars Sinai Medical Care Foundation
Los Angeles, CA








Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By